The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Sparkle1.. VHCP are an early stage investor (venture) as opposed to private equity (late stage). I would be surprised if their strategy is to take private, rather they look for later stage private investments to take public or early stage public investments.
A BoD is or should be reluctant to raise cash via a dilution and PIs should not encourage it as if they do it will likely be a placing at a discount which will only benefit larger investors and devalue our shareholdings.
Not sure of gender OR agenda, pinch of salt springs to mind imo
you have a lot of men on this board under your spell eva :) but we are still not sure of your gender lol.
good luck with your investments, never get too ****y as I've learnt the hard way - easy come, easy go, especially on this aim casino...
Well, even if they wanted to raise a cool 20 million to wine and dine, it's still only a dillution of 10 million shares at these prices. No biggy and I am sure they will be oversubscribed again.
Oilornothing,
No..but it would make sense for SNG to raise more cash as they will have more options open to them and more bargaining power in partnership negotiations :-)
Anyway , Cash is king in the financial markets as Data is king in the scientific world .... we never have enough of both :-)
Lol..this is the first time anyone has taken umbrage against my remarks (most of which are in jest) but so be it.
I'm happy for all you other eva white knights to filter me but i stand by my comments the other day. I don't get why someone would be divulging detailed information on their trades other than blow smoke up their own backside, there are loads of editing tools out there so screenshots don't prove anything either. And then the fact that anyone who hasn't commented here prior to the rise, is someone to cast suspicion over, no one cares, get a f*cking life, its only a bulletin board not the a members only club!
One of my decisions to invest here was that SNG had a fund raising in March 2020 for £14m so I assumed they had adequate resources going forward. I don't know what their cash burn is but I still don't think they will need to raise further cash in the near future.
I don't think Mac was refering to a placing for a partner though was he!
I was aware of your point
The US fund is raising it's position and your point is that they would'nt be raising their position IF THEY thought there was going to be a share placement ...
My point is that there could very well be a share placement but EXCLUSIVELY for the Partner
It doesn't matter who buys. Its all relative.
Woodstock, the peer report is not essential it is simply how they will inform the scientific community/public. The peer review will not even assess the whole dataset. What is essential is the regulatory agencies/licencees view of the entire dataset.
Woodstock - SNG’s phase 2 trials had many of the features of a phase 3 study.
-Randomisation (double blind) being key Which is not a phase 2 requirement.
The only benefit phase 3 offers is more numbers, I think the case for EUA FDA without a phase 3 is strong here. A phase 3 can always be run in parallel with EUA
“ Phase III of a clinical trial usually involves up to 3,000 participants who have the condition that the new medication is meant to treat. Trials in this phase can last for several years.
The purpose of phase III is to evaluate how the new medication works in comparison to existing medications for the same condition. To move forward with the trial, investigators need to demonstrate that the medication is at least as safe and effective as existing treatment options.
To do this, investigators use a process called randomization. This involves randomly choosing some participants to receive the new medication and others to receive an existing medication.
Phase III trials are usually double-blind, which means that neither the participant nor the investigator knows which medication the participant is taking. This helps to eliminate bias when interpreting results.
The FDA usually requires a phase III clinical trial before approving a new medication. Due to the larger number of participants and longer duration or phase III, rare and long-term side effects are more likely to show up during this phase.
If investigators demonstrate that the medication is at least as safe and effective as others already on the market, the FDA will usually approve the medication.”
We have to remind ourselves that COPD treatment happens to be great at making coronavirus patients survive, purely by luck.
The stock remains high risk because we need trial 3.
I say buy,but be willing to set fire to hard currency. I know but she could drop down to 40p.
Our path with this company is good but remember it could rain.
Woodie
are they a fund? more like private equity - could take it private?
Nolupus....I think you missed my point...
We have a fund adding today....That is very different to a Pharma Partner
paying above market SP......
We must remember although stage 2 trials were mind blowing. Stage 3 trials are more important. Look at the companies that are in stage 3 of vaccine trials.
On a brighter note, I believe we could be onto something good.
Woodie
Not the only treatment; yank have one
We could see another cash raise. The bod and staff deserve a bonus.
The peer report is essential and shouldn't dismiss.
We must not dismiss trial 3 of Sgn001.
I am mildly optimistic but we must keep an open mind.
We must remain open minded of COPD trials because the research has been going on for years.
I am rather excited about Sng016 home trials.
No cash needed as SNG will be sold before the last penny is spent.
This is something I have thought about....at current prices it makes sense to raise cash if they were going it alone. I think they are looking for a partner or takeover to take it forward...the directors are all quite old...having worked on this for 15 years ...now that they have not only made money...but also brought the only viable treatment for covid I think they will be happy with a takeover. Imo
Manifesto,
I cannot agree with your argument as we have already seen fund raising being done by partners at a higher price than the market SP ...
It's possible to see a Gilead or a Pfizer taking a stake at 250/300 even if the sp is at 200 ....
why would they want to dilute SP this month when they are trying to cut a deal with x or y and such a deal would need to increase the forecasted earnings of x or y. They'd only raise cash if they decided to go it alone for another while. End of.
I am sure our RNS today tells you there is no placing on the horizon..
If they thought there was a remote chance they could have got a discount in a
placing they would not repeatedly top up at full market price.......IMHO!
Mactheknife,
Your post makes perfect sense to me and therefore I agree with you :-)
My only reply is that they are concentrated on the science at this time and that the finance is coming after .
My opinion is that they will do a placing deal with the future partner as well as getting an upfront payment ... this would make perfect sense to see the partner taking a 10-25% stake in Synairgen ...